Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2019 and announced recent business highlights.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:30 p.m. ET.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of Stealth BioTherapeutics Stealth's Form 20-F filed with the SEC on April 1, 2020. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so if our views change.

Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report full year 2019 financial results on Wednesday, April 1, 2020, before the market opens.

Benzinga Pro's Stocks To Watch For Friday Apple (AAPL) - Shares were modestly higher Friday morning following several items: 1. Piper Jaffray analyst Mike Olson raised his price target on Apple from $290 ...

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced top-line data from the Phase 3 MMPOWER-3 trial evaluating elamipretide for treatment of patients with primary mitochondrial myopathy (PMM). The study did not meet its primary endpoints assessing changes in the six-minute walk test and Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score. Safety results showed that treatment with elamipretide was well tolerated with most adverse events mild to moderate in severity.

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has completed a $20 million private placement with Morningside Venture (I) Investments Limited ("Morningside"). As part of the financing, Morningside purchased 152,858,460 ordinary shares at a price of US $0.13084 per ordinary share. The last reported closing price of the Company's American Depositary Shares (ADS) on Nasdaq was $1.57; each ADS represents 12 ordinary shares.

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens.

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...

NEW YORK, NY / ACCESSWIRE / April 1, 2020 / Stealth BioTherapeutics Corp. (NASDAQ:MITO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on April 1, 2020 ...

A Newton biotech startup is making major changes after a late-stage drug trial failure, announcing this week that it has laid off 60% of its staff.

Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced positive results from its retrospective natural history study, clinical protocol SPIBA-001, evaluating the efficacy of subcutaneous injections of elamipretide relative to a natural history control comprised of 19 propensity score matched subjects with Barth syndrome (Barth). Subjects receiving elamipretide for up to one year during the TAZPOWER trial and open-label extension showed a mean improvement of greater than 80 meters on their six-minute walk test (6MWT), the primary efficacy endpoint, compared to less than one meter for subjects in the natural history group evaluated over the same time period (p=0.0005). Patients also showed statistically significant improvements in several key secondary endpoints, including muscle strength and sit-to-stand evaluations. Additional analysis of these data will be presented at an upcoming medical meeting.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19 at 12:30 p.m. ET.

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the initiation of a first-in-human Phase 1 trial evaluating its second generation pipeline compound, SBT-272, in healthy subjects.

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the 40th Annual Cowen Health Care Conference in Boston, MA on Wednesday, March 4 at 10:40 am ET.

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...